Contact us to learn more about partnering opportunities

BerGenBio is a premier partner for pharmaceutical companies seeking to drive efficiencies and derisk their drug discovery programs
CELLSELECT RNAi™
CellSelectRNAi is a suite of technologies for the production and screening of large libraries of shRNA RNA interference elements.
Typically we produce and screen 100-300 shRNAs per target gene, guaranteeing not only identification of several highly effective shRNAs but also a collection of shRNAs that trigger a range of lesser knockdowns, producing an ‘epi-allelic series’.
Features
- “Ask The Cell” phenotypic genetic screening
- 100-300 shRNA per gene
- Multiple effective RNAi sequences to guard against off-target effects
- Retroviral delivery for reliable sustained knockdown
- Single gene, gene family or druggable-genome scale libraries
Example Applications
Single gene libraries
- Drug target validation in in vivo/in vitro models
- Epi-allelic analysis to determine required inhibition for therapeutic effect
- Long term in vivo studies
- Mechanism of action studies
Gene family libraries
- Validation of true target of promiscuous drug
- Mimic effects of promiscuous drugs by mimicking different degrees of knockdown for each target
Druggable-genome libraries
- Dominant effector genetic screening for complex phenotypes
- Novel drug target candidate discovery, therapeutic mechanism of action studies
